Esperion Therapeutics to Present at 34th Annual J.P. Morgan Healthcare Conference
January 06 2016 - 4:30PM
Esperion Therapeutics, Inc. (NASDAQ:ESPR), a pharmaceutical company
focused on developing and commercializing first-in-class, oral,
low-density lipoprotein cholesterol (LDL-C) lowering therapies for
the treatment of patients with hypercholesterolemia, today
announced that president and chief executive officer, Tim M.
Mayleben, will present at the 34th Annual J.P. Morgan Healthcare
Conference in San Francisco, CA on Wednesday, January 13, 2016 at
2:00 p.m. Pacific Time/5:00 p.m. Eastern Time.
A live, listen-only webcast of the presentation
can be accessed on the investor relations section of the Esperion
website at www.esperion.com. A webcast replay of the
presentation will be available approximately one hour after
completion and will be archived on the Company's website for 90
days following the event.
Esperion’s Commitment to Cardiometabolic
Disease
Esperion is committed to improving the lives of patients with
hypercholesterolemia by developing therapies to lower LDL-C.
Esperion scientists discovered ETC-1002 and the LDL-C lowering
therapy is in late stage development. Esperion plans to develop
both ETC-1002 and a fixed dose combination of ETC-1002 and
ezetimibe with a particular focus on patients with
hypercholesterolemia who are considered intolerant of statin
therapy. It is estimated that approximately 10% of patients who are
prescribed statins, 3.5 million patients in the U.S., are
considered statin intolerant.
About Esperion Therapeutics
Esperion Therapeutics, Inc. is a
pharmaceutical company focused on developing and commercializing
first-in-class, oral, LDL-C lowering therapies for the treatment of
patients with hypercholesterolemia. ETC-1002 (bempedoic acid), the
Company’s lead product candidate, is an inhibitor of ATP Citrate
Lyase, a well-characterized enzyme on the cholesterol biosynthesis
pathway. ETC-1002 inhibits cholesterol synthesis, decreases
intracellular cholesterol, up-regulates LDL-receptors, and causes
increased LDL-C clearance and reduced plasma levels of LDL-C. For
more information, please visit www.esperion.com and
follow us on Twitter at https://twitter.com/EsperionInc.
Media Contact:
Elliot Fox
W2O Group
212.257.6724
efox@w2ogroup.com
Investor Contact:
Mindy Lowe
Esperion Therapeutics, Inc.
734.887.3903
mlowe@esperion.com
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jul 2023 to Jul 2024